1. Home
  2. RVP vs AKTX Comparison

RVP vs AKTX Comparison

Compare RVP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Retractable Technologies Inc.

RVP

Retractable Technologies Inc.

HOLD

Current Price

$0.69

Market Cap

20.9M

Sector

Health Care

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$7.54

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVP
AKTX
Founded
1994
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
18.2M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
RVP
AKTX
Price
$0.69
$7.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
11.8K
28.4K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$38,266,211.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.78
N/A
52 Week Low
$0.60
$0.12
52 Week High
$1.14
$29.32

Technical Indicators

Market Signals
Indicator
RVP
AKTX
Relative Strength Index (RSI) 53.30 41.06
Support Level $0.66 $0.21
Resistance Level $0.74 $15.50
Average True Range (ATR) 0.01 0.67
MACD 0.00 0.02
Stochastic Oscillator 85.47 44.00

Price Performance

Historical Comparison
RVP
AKTX

About RVP Retractable Technologies Inc.

Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: